Aphria has received its European Union Good Manufacturing Practices certification in respect of medicinal products for human use and investigational medicinal products for human use, from the Malta Medicines Authority ("MMA") at the Company's subsidiary, ARA - Avanti Rx Analytics.
"Aphria selected the MMA to perform the EU GMP audit as the criteria and certification thresholds established by the MMA are among the most stringent and demanding in the EU," the team with the company explains. "The certification will allow the Company to ship bulk and finished dried flower, as well as bulk and finished cannabis oil for medicinal use in permitted jurisdictions throughout the European Union."
"We believe that this is a game changer for Aphria and will significantly advance our leadership in permissible medical cannabis markets across Europe, where demand for product is strong," said Irwin D. Simon, Chief Executive Officer. "With 2.4 million square feet of licensed production capacity of up to 255,000 kilograms, state-of-the-art greenhouses and labs, and our global infrastructure, we believe Aphria is well positioned to lead in the Canadian and international markets."
Aphria's German operations have been preparing for the importation of EU-GMP certified cannabis from Canada, allowing for shipments to the Company's German subsidiary CC Pharma GmbH in order to leverage CC Pharma's expansive in-country distribution network. The Company anticipates that its first shipments of medical cannabis to CC Pharma will occur in its fourth quarter of its fiscal 2020.
For more information:
Aphria Inc.
1-844-427-4742
1-844-4-APHRIA
info@aphria.com
aphriainc.com